Multidrug Resistance in Lung Cancer Cells
Author Information
Author(s): J.G. Reeve, P.H. Rabbitts, P.R. Twentyman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, Medical Research Council Centre
Hypothesis
The study investigates the role of P-glycoprotein and EGF receptor expression in multidrug resistance of lung cancer cell lines.
Conclusion
The MDR variant of the large cell lung carcinoma cell line COR-L23 shows reduced EGF receptor expression and no hyperexpression of P-glycoprotein.
Supporting Evidence
- The MDR variant of COR-L23 shows no evidence of P-glycoprotein hyperexpression.
- The EGF receptor number is significantly reduced in the MDR variant compared to the parent line.
- Previous studies indicated that EGF receptor numbers can increase with MDR, but this study found the opposite.
Takeaway
Some lung cancer cells can become resistant to drugs without making more of a protein called P-glycoprotein, and they may have fewer EGF receptors.
Methodology
The study derived MDR variants of lung cancer cell lines and examined their expression of P-glycoprotein and EGF receptors using various assays.
Limitations
The study does not explore all potential mechanisms of MDR and focuses primarily on P-glycoprotein and EGF receptor expression.
Want to read the original?
Access the complete publication on the publisher's website